摘要:
We synthesized methylvesamicol analogs 13-16 and investigated the binding characteristics of 2-[4-phenylpiperidino]cyclohexanol (vesamicol) and methylvesamicol analogs 13-16, with a methyl group introduced into the 4-phenylpiperidine moiety, to sigma receptors (sigma-1, sigma-2) and to vesicular acetylcholine transporters (VAChT) in membranes of the rat brain and liver. In competitive inhibition studies, (-)-o-methylvesamicol [(-)-OMV] (13) (K-i = 6.7 nM), as well as (-)-vesamicol (K-i = 4.4 nM), had a high affinity for VAChT. (+)-p-Methylvesamicol [(+)-PMV] (16) (K-i = 3.0 nM), as well as SA4503 (K-i = 4.4 nM), reported as a sigma-1 mapping agent for positron emission tomography (PET), had a high affinity for the sigma-1 receptor. The binding affinity of (+)-PMV (1-16) for the sigma-1 receptor (K-i = 3.0 nM) was about 13 times higher than that for the sigma-2 (sigma-2) receptor (K-i = 40.7 nM). (+)-PMV (16) (K-i = 199 nM) had a much lower affinity for VAChT than SA4503 (K-i = 50.2 nM) and haloperidol (K-i = 41.4 nM). These results showed that the binding characteristics of (-)-OMV (13) to VAChT were similar to those of (-)-vesamicol and that (+)-PMV (16) bound to the sigma-1 receptor with high affinity. In conclusion, (-)-OMV (13) and (+)-PMV (16). which had a Suitable structure, with a methyl group for labeling with C-11, may become not only a new VAChT ligand and a new type of sigma receptor ligand, respectively, but may also become a new target compound of VAChT and the sigma-1 receptor radioligand for PET, respectively. (c) 2005 Elsevier Ltd. All rights reserved.